These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39311002)

  • 1. Sustained linagliptin administration: superior glycemic control and less pancreatic injury in diabetic rats.
    Zakaria EM; El-Gamal SF; Mahmoud SM; El-Nahas HM; El-Bassossy HM
    Pharm Dev Technol; 2024 Oct; 29(8):874-885. PubMed ID: 39311002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of linagliptin in preventing the pathological progression of hepatic fibrosis in high fat diet and streptozotocin-induced diabetic obese rats.
    Aboulmagd YM; El-Bahy AAZ; Menze ET; Azab SS; El-Demerdash E
    Eur J Pharmacol; 2020 Aug; 881():173224. PubMed ID: 32454118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transmucosal delivery of linagliptin for the treatment of type- 2 diabetes mellitus by ultra-thin nanofibers.
    Modgill V; Garg T; Goyal AK; Rath G
    Curr Drug Deliv; 2015; 12(3):323-32. PubMed ID: 25410375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
    Chen L; Klein T; Leung PS
    Curr Mol Med; 2012 Sep; 12(8):995-1004. PubMed ID: 22804249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice.
    Kanda J; Furukawa M; Izumo N; Shimakura T; Yamamoto N; Takahashi HE; Wakabayashi H
    Drug Discov Ther; 2020 Nov; 14(5):218-225. PubMed ID: 33116039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose.
    Salheen SM; Panchapakesan U; Pollock CA; Woodman OL
    PLoS One; 2015; 10(11):e0143941. PubMed ID: 26618855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
    Forst T; Uhlig-Laske B; Ring A; Ritzhaupt A; Graefe-Mody U; Dugi KA
    Diabetes Obes Metab; 2011 Jun; 13(6):542-50. PubMed ID: 21352464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
    Tan X; Hu J
    Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vildagliptin loaded triangular DNA nanospheres coated with eudragit for oral delivery and better glycemic control in type 2 diabetes mellitus.
    Baig MMFA; Khan S; Naeem MA; Khan GJ; Ansari MT
    Biomed Pharmacother; 2018 Jan; 97():1250-1258. PubMed ID: 29145151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP) sub-study 1.
    Kurozumi A; Okada Y; Satoh H; Inoue I; Chimori H; Akita E; Shiraiwa T; Fujitani Y; Mita T; Gosho M; Watada H
    Endocr J; 2018 Apr; 65(4):415-425. PubMed ID: 29367471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in Type 2 diabetes.
    Hardigan T; Yasir A; Abdelsaid M; Coucha M; El-Shaffey S; Li W; Johnson MH; Ergul A
    Am J Physiol Regul Integr Comp Physiol; 2016 Sep; 311(3):R466-77. PubMed ID: 27357799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice.
    Hutch CR; Roelofs K; Haller A; Sorrell J; Leix K; D'Alessio DD; Augustin R; Seeley RJ; Klein T; Sandoval DA
    Diabetologia; 2019 Oct; 62(10):1928-1937. PubMed ID: 31414143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.
    Horie Y; Kanada S; Watada H; Sarashina A; Taniguchi A; Hayashi N; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2011 Jul; 33(7):973-89. PubMed ID: 21723606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice.
    Fushimi Y; Obata A; Sanada J; Nogami Y; Ikeda T; Yamasaki Y; Obata Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
    Sci Rep; 2021 Aug; 11(1):16120. PubMed ID: 34373487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Telmisartan and Linagliptin Preserves Pancreatic Islet Cell Function and Morphology in db/db Mice.
    Zhao S; Chan LK; Chen L; Cheng TW; Klein T; Leung PS
    Pancreas; 2016 Apr; 45(4):584-92. PubMed ID: 26495783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
    Aronson R
    Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
    Kanasaki K
    Clin Sci (Lond); 2018 Feb; 132(4):489-507. PubMed ID: 29491123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.
    Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Pharmacol Rep; 2009; 61(5):899-908. PubMed ID: 19904014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
    Aletti R; Cheng-Lai A
    Cardiol Rev; 2012; 20(1):45-51. PubMed ID: 22143285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
    Rizos CV; Filippatos TD; Elisaf MS
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.